Literature DB >> 14604996

Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells.

Matthias Neid1, Kaustubh Datta, Susann Stephan, Ila Khanna, Soumitro Pal, Leslie Shaw, Morris White, Debabrata Mukhopadhyay.   

Abstract

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), the critical molecule in tumor angiogenesis, is regulated by different stimuli, such as hypoxia and oncogenes, and also by growth factors. Previously we have shown that in AsPC-1 pancreatic adenocarcinoma cells, insulin-like growth factor receptor (IGF-IR) regulates VPF/VEGF expression. Insulin receptor substrate-1 and -2 (IRS-1 and IRS-2), two major downstream molecules of IGF-1R, are known to be important in the genesis of diabetes. In this study, we have defined a new role of IRS in angiogenesis. Both of the IRS proteins modulate VPF/VEGF expression in pancreatic cancer cells by different mechanistic pathways. The Sp1-dependent VPF/VEGF transcription is regulated mainly by IRS-2. Protein kinase C-zeta (PKC-zeta) plays a central role in VPF/VEGF expression and acts as a switching element. Furthermore, we have also demonstrated that the phosphatidylinositol 3-kinase pathway, but not the Ras pathway, is a downstream event of IRS proteins for VPF/VEGF expression in AsPC-1 cells. Interestingly, like renal cancer cells, in AsPC-1 cells PKC-zeta leads to direct Sp1-dependent VPF/VEGF transcription; in addition, it also promotes a negative feedback loop to IRS-2 that decreases the association of IRS-2/IGF-1R and IRS-2/p85. Taken together, our results show that in AsPC-1 pancreatic carcinoma cells, Sp1-dependent VPF/VEGF transcription is controlled by IGF-1R signaling through IRS-2 proteins and modulated by a negative feedback loop of PKC-zeta to IRS-2. Our data also suggest that IRS proteins, which are known to play crucial roles in IGF-1R signaling, are also important mediators for tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604996     DOI: 10.1074/jbc.M303975200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Imaging human pancreatic cancer xenografts by targeting mutant KRAS2 mRNA with [(111)In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles.

Authors:  Nariman V Amirkhanov; Kaijun Zhang; Mohan R Aruva; Mathew L Thakur; Eric Wickstrom
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

2.  Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?

Authors:  Dimitra Grapsa; Muhammad Wasif Saif; Konstantinos Syrigos
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

Review 3.  Molecular targeted approaches for treatment of pancreatic cancer.

Authors:  Z Q Huang; A K Saluja; V Dudeja; S M Vickers; D J Buchsbaum
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Jason B Douglas; Debra T Silverman; Michael N Pollak; Yuzhen Tao; Amr S Soliman; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-10       Impact factor: 4.254

5.  Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.

Authors:  Xiaoqun Dong; Milind Javle; Kenneth R Hess; Rachna Shroff; James L Abbruzzese; Donghui Li
Journal:  Gastroenterology       Date:  2010-04-21       Impact factor: 22.682

6.  miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2.

Authors:  Yadong Ma; Hongyi Zhang; Xiaolong He; Hongxiong Song; Yayong Qiang; Yi Li; Jixue Gao; Ziming Wang
Journal:  Tumour Biol       Date:  2015-05-28

7.  Protein kinase C-zeta phosphorylates insulin receptor substrate-1, -3, and -4 but not -2: isoform specific determinants of specificity in insulin signaling.

Authors:  Sihoon Lee; Edward G Lynn; Jeong-A Kim; Michael J Quon
Journal:  Endocrinology       Date:  2008-01-17       Impact factor: 4.736

Review 8.  Monoclonal antibodies in the treatment of pancreatic cancer.

Authors:  Zhi-Qiang Huang; Donald J Buchsbaum
Journal:  Immunotherapy       Date:  2009-03       Impact factor: 4.196

9.  Insulin receptor substrate (IRS)-2, not IRS-1, protects human neuroblastoma cells against apoptosis.

Authors:  Bhumsoo Kim; Eva L Feldman
Journal:  Apoptosis       Date:  2009-05       Impact factor: 4.677

10.  Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells.

Authors:  Lu Jiang; Yongchang Chen; Jianrong Sang; Yueying Li; Ting Lan; Ying Wang; Yan Tao; Hai Qian
Journal:  Biomed Rep       Date:  2013-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.